Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 10/20 | 0.47 |
| ▸ | IL2 | P60568 | 10/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.44 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605261 | 1.00 | PARP1 (0.47) | PARP1ALBIL2HRH4KDR | |
| SCHEMBL3615341 | 1.00 | PARP1 (0.47) | PARP1ALBIL2HRH4KDR | |
| Trifluoroacetic Acid SCHEMBL3612189 | 0.94 | ALB (0.47) | PARP1ALBIL2HRH4KDR | |
| Trifluoroacetic Acid SCHEMBL3606633 | 0.94 | ALB (0.47) | PARP1ALBIL2HRH4KDR | |
| SCHEMBL3597204 | 0.93 | CDK2 (0.50) | PARP1DYRK1AMLLT1 | |
| SCHEMBL3597200 | 0.93 | CDK2 (0.50) | PARP1DYRK1AMLLT1 | |
| SCHEMBL3596393 | 0.86 | PYGL (0.50) | PARP1HRH4KDRSMYD3FLT3 | |
| SCHEMBL3605675 | 0.86 | SMYD3 (0.50) | PARP1KDRSMYD3FLT3 | |
| SCHEMBL3611578 | 0.86 | SMYD3 (0.50) | PARP1KDRSMYD3FLT3 | |
| SCHEMBL3596390 | 0.86 | PYGL (0.50) | PARP1HRH4KDRSMYD3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | PARP1 156/4885ALB 4386/4885IL2 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.